Protecting the vulnerable during COVID-19: Treating and preventing chronic disease disparities.

The coronavirus disease 2019 (COVID-19) pandemic has exacerbated health disparities across ethnic and socioeconomic groups. Non-communicable diseases (NCDs) - such as hypertension, diabetes, and obstructive lung diseases - are key drivers of this widening gap, because they disproportionately afflict vulnerable populations. Vulnerable populations with non-communicable diseases, in turn, are disproportionately affected by COVID-19 itself - but also at increased risk of poor outcomes from those underlying conditions. Proven strategies for NCD control must be adapted to help vulnerable patients react to these dual threats. We detail six key policy interventions - task shifting, workforce protection, telehealth and mobile services, insurance restructuring and increased funding for NCDs, prescription policies for NCDs and community partnerships - to bridge this care gap. Long-term integration of these care models post-COVID-19 may prevent care shocks during future pandemics, bolstering emerging universal primary care models.

Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies.

Osteoporosis is common in human immunodeficiency virus (HIV)-infected persons. The etiology of osteoporosis in HIV-infected patients is likely multifactorial, involving traditional risk factors such as low body weight, hypogonadism, and smoking, as well as direct effects of chronic HIV infection and antiretroviral therapy. Emerging evidence suggests that the increasing prevalence of osteoporosis in HIV-infected persons translates into a higher risk of fracture, likely leading to excess morbidity and mortality as the HIV-infected population ages. This review addresses the epidemiology of osteoporosis, discusses the causes of low bone mineral density in HIV-infected persons, including the impact of specific antiretroviral therapies, and offers recommendations on screening and treating vitamin D deficiency and osteoporosis.

Postoperative hypoparathyroidism: medical and surgical therapeutic options.

BACKGROUND: Hypoparathyroidism occurs when the parathyroid glands, through lack of secretion of or resistance to parathyroid hormone (PTH), are unable to maintain calcium homeostasis. Transient and permanent hypoparathyroidism are most commonly seen as complications of neck surgery, resulting from devascularization of the parathyroids, unintentional resection, or accidental coagulation of the parathyroids. SUMMARY: Although strategies for treatment of transient and permanent hypoparathyroidism differ, the classical approach involves supplementation with calcium and vitamin D or its analogues with the major goal of achieving low normal serum calcium and normal serum phosphorus. There are a variety of calcium and vitamin D preparations available for use in the treatment of symptomatic hypoparathyroidism. In selecting the appropriate vitamin D sterol for treatment, it is important to consider the pharmocodynamics, the potency at the tissue level, the rapidity of action, and ease of reversal of toxicity. Drawbacks to conventional therapy, including narrow therapeutic window and propensity for hypercalciuria and hypercalcemia, have prompted investigation into alternatives, namely PTH replacement and parathyroid gland autotransplantation. CONCLUSION: Long-term supplementation with vitamin D or its analogues and oral calcium is the mainstay of management of postoperative hypoparathyroidism; however, PTH replacement strategies with either PTH or parathyroid gland autotransplantation are emerging as alternative strategies to avoid the complications of conventional therapy.